NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.43
  • Forecasted Upside: -31.15 %
  • Number of Analysts: 8
  • Breakdown:
  • 2 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$13.69
▲ +0.02 (0.15%)
1 month | 3 months | 12 months
Get New AMAG Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMAG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMAG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.43
▼ -31.15% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for AMAG Pharmaceuticals in the last 3 months. The average price target is $9.43, with a high forecast of $13.75 and a low forecast of $6.00. The average price target represents a -31.15% upside from the last price of $13.69.
Hold
The current consensus among 8 polled investment analysts is to hold stock in AMAG Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings
5/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 2 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 2 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 2 sell ratings
10/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/2/2020SVB LeerinkBoost Price TargetMarket Perform$10.00 ➝ $13.65Medium
i
10/2/2020HC WainwrightDowngradeBuy ➝ Neutral$14.00 ➝ $13.75Medium
i
Rating by D. Tsao at HC Wainwright
10/1/2020Piper SandlerUpgradeUnderweight ➝ NeutralHigh
i
8/19/2020TruistBoost Price Target$7.00 ➝ $10.00Low
i
8/18/2020BarclaysDowngradeOverweight ➝ Equal Weight$10.89 ➝ $10.00Medium
i
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$9.00 ➝ $10.00High
i
8/6/2020HC WainwrightBoost Price TargetBuy$10.00 ➝ $14.00Low
i
Rating by D. Tsao at HC Wainwright
7/23/2020Needham & Company LLCReiterated RatingHoldHigh
i
5/15/2020SunTrust BanksBoost Price TargetHold$6.00 ➝ $7.00Low
i
5/12/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$9.00 ➝ $8.00High
i
5/12/2020SVB LeerinkLower Price TargetMarket Perform$11.00 ➝ $9.00High
i
5/12/2020HC WainwrightBoost Price TargetBuy$9.00 ➝ $10.00High
i
4/29/2020HC WainwrightReiterated RatingBuy$9.00Medium
i
4/17/2020HC WainwrightLower Price TargetBuy$12.00 ➝ $9.00High
i
3/9/2020Needham & Company LLCReiterated RatingHoldHigh
i
3/8/2020BarclaysReiterated RatingBuy$11.00High
i
Rating by Balaji Prasad at Barclays PLC
3/5/2020Piper SandlerLower Price Target$9.00 ➝ $7.00Medium
i
3/3/2020HC WainwrightLower Price TargetBuy$16.00 ➝ $12.00Low
i
11/3/2019BarclaysReiterated RatingBuy$16.00 ➝ $14.00High
i
Rating by Balaji Prasad at Barclays PLC
10/30/2019Piper Jaffray CompaniesDowngradeNeutral ➝ Underweight$9.00 ➝ $6.00High
i
Rating by Christopher Raymond at Piper Jaffray Companies
10/25/2019Needham & Company LLCReiterated RatingHoldLow
i
8/8/2019HC WainwrightReiterated RatingBuy$16.00High
i
Rating by D. Tsao at HC Wainwright
8/7/2019Piper Jaffray CompaniesReiterated RatingNeutral$9.00High
i
8/1/2019HC WainwrightInitiated CoverageBuy ➝ Buy$16.00High
i
Rating by D. Tsao at HC Wainwright
6/24/2019CowenReiterated RatingHold$13.00High
i
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$19.00Medium
i
5/14/2019SunTrust BanksSet Price TargetHold$13.00Low
i
Rating by Gregg Gilbert at SunTrust Banks, Inc.
3/19/2019SunTrust BanksInitiated CoverageHold ➝ HoldLow
i
3/14/2019Cantor FitzgeraldReiterated RatingHold$17.00 ➝ $14.00Medium
i
Rating by M. Lillis at Cantor Fitzgerald
1/16/2019B. RileySet Price TargetBuy$21.00Medium
i
Rating by David Buck at B. Riley
12/14/2018B. RileyReiterated RatingBuy ➝ Buy$29.00 ➝ $20.50Medium
i
Rating by D. Buck at B. Riley
11/23/2018Cantor FitzgeraldReiterated RatingNeutralHigh
i
Rating by M. Lillis at Cantor Fitzgerald
11/13/2018Cantor FitzgeraldSet Price TargetHold$18.00Medium
i
Rating by William Tanner at Cantor Fitzgerald
11/6/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$20.00 ➝ $18.00Medium
i
11/2/2018Cantor FitzgeraldSet Price TargetHold$18.00High
i
Rating by William Tanner at Cantor Fitzgerald
11/1/2018CowenSet Price TargetHold$19.00High
i
Rating by Ken Cacciatore at Cowen Inc
9/26/2018Cantor FitzgeraldSet Price TargetHold$18.00Low
i
Rating by William Tanner at Cantor Fitzgerald
9/20/2018Deutsche Bank AktiengesellschaftSet Price TargetHold$23.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/6/2018B. RileyBoost Price TargetBuy ➝ Buy$30.00 ➝ $31.00Medium
i
Rating by D. Buck at B. Riley
8/3/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Hold$17.00 ➝ $18.00High
i
Rating by William Tanner at Cantor Fitzgerald
8/3/2018Jefferies Financial GroupReiterated RatingHold$22.00High
i
6/15/2018B. RileyUpgradeNeutral ➝ Buy$23.00 ➝ $30.00Low
i
Rating by D. Buck at B. Riley
6/15/2018Janney Montgomery ScottDowngradeBuy ➝ Neutral$20.00High
i
5/21/2018SVB LeerinkInitiated CoverageMarket Perform$26.00 ➝ $24.65Medium
i
Rating by J. Schwartz at SVB Leerink LLC
3/14/2018B. RileyBoost Price TargetNeutral ➝ Neutral$16.00 ➝ $23.00Medium
i
Rating by D. Buck at B. Riley
3/5/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$21.00 ➝ $20.00Low
i
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$20.00Medium
i
2/28/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.00Medium
i
Rating by Thomas Smith at Morgan Stanley
2/27/2018CowenReiterated RatingHold$25.00Medium
i
Rating by Ken Cacciatore at Cowen Inc
2/27/2018Cantor FitzgeraldReiterated RatingHold$17.00Medium
i
2/15/2018Piper Jaffray CompaniesReiterated RatingHold ➝ NeutralMedium
i
2/15/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$16.65 ➝ $45.00High
i
Rating by Ken Trbovich at Janney Montgomery Scott
2/14/2018Cantor FitzgeraldReiterated RatingHold$17.00High
i
2/2/2018SVB LeerinkReiterated RatingMarket PerformHigh
i
Rating by J. Schwartz at SVB Leerink LLC
1/29/2018B. RileyReiterated RatingHold$16.00Low
i
Rating by D. Buck at B. Riley
1/18/2018Piper Jaffray CompaniesReiterated RatingHold$15.00High
i
1/16/2018B. RileyReiterated RatingHold$16.00Medium
i
Rating by D. Buck at B. Riley
12/7/2017B. RileyInitiated CoverageNeutral ➝ Neutral$16.00Low
i
Rating by D. Buck at B. Riley
11/5/2017Jefferies Financial GroupReiterated RatingBuy$16.00N/A
i
11/3/2017Morgan StanleyLower Price TargetOverweight$26.00 ➝ $22.00N/A
i
Rating by Thomas Smith at Morgan Stanley
10/23/2017Janney Montgomery ScottReiterated RatingHoldN/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
10/23/2017Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Neutral$18.00N/A
i
10/17/2017Janney Montgomery ScottReiterated RatingHoldN/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
9/28/2017Cantor FitzgeraldReiterated RatingHold$21.00High
i
9/8/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$26.00High
i
8/31/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$24.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/10/2017CowenReiterated RatingHoldHigh
i
7/24/2017Cantor FitzgeraldReiterated RatingHoldLow
i
Rating by William Tanner at Cantor Fitzgerald
7/7/2017Deutsche Bank AktiengesellschaftSet Price TargetHold$28.00 ➝ $24.00Medium
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
7/7/2017CitigroupLower Price TargetHold$24.00Low
i
6/26/2017Cantor FitzgeraldReiterated RatingHold$23.00Medium
i
Rating by William Tanner at Cantor Fitzgerald
6/1/2017BarclaysReiterated RatingEqual Weight$25.00 ➝ $20.00Low
i
5/15/2017BarclaysReiterated RatingHold$25.00N/A
i
5/5/2017BarclaysReiterated RatingHold$25.00High
i
5/3/2017Jefferies Financial GroupReiterated RatingBuy$40.00 ➝ $34.00High
i
Rating by David Steinberg at Jefferies Financial Group Inc.
5/2/2017Cantor FitzgeraldReiterated RatingHold$23.00High
i
Rating by William Tanner at Cantor Fitzgerald
4/20/2017Jefferies Financial GroupSet Price TargetBuy$40.00Medium
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/18/2017Jefferies Financial GroupSet Price TargetBuy$40.00High
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/6/2017Cantor FitzgeraldBoost Price TargetNeutral$24.00 ➝ $25.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
2/28/2017Cantor FitzgeraldReiterated RatingNeutralN/A
i
Rating by William Tanner at Cantor Fitzgerald
2/27/2017Cantor FitzgeraldSet Price TargetHold$24.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
2/15/2017Jefferies Financial GroupReiterated RatingBuy$45.00 ➝ $40.00N/A
i
2/14/2017Cantor FitzgeraldSet Price TargetHold$24.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
2/3/2017CowenDowngradeOutperform ➝ Market PerformN/A
i
2/2/2017Cantor FitzgeraldSet Price TargetHold$25.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
2/2/2017GuggenheimLower Price TargetBuy$42.00 ➝ $28.00N/A
i
1/31/2017JPMorgan Chase & Co.Set Price TargetHold$24.00N/A
i
Rating by Jessica Fye at JPMorgan Chase & Co.
1/20/2017Cantor FitzgeraldSet Price TargetHold$25.00N/A
i
1/12/2017Cantor FitzgeraldReiterated RatingNeutral$33.00N/A
i
1/11/2017Needham & Company LLCDowngradeBuy ➝ HoldN/A
i
1/10/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralN/A
i
1/10/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$39.00 ➝ $25.00N/A
i
Rating by J. Schwartz at SVB Leerink LLC
1/9/2017Raymond JamesReiterated RatingMarket Perform ➝ UnderperformN/A
i
1/3/2017Janney Montgomery ScottReiterated RatingBuy ➝ Buy$45.00N/A
i
12/21/2016Cantor FitzgeraldReiterated RatingNeutral$33.00N/A
i
12/15/2016Cantor FitzgeraldInitiated CoverageNeutral$33.00N/A
i
11/7/2016GuggenheimInitiated CoverageBuy$42.00N/A
i
11/4/2016JPMorgan Chase & Co.Reiterated RatingHold$33.00N/A
i
10/26/2016Needham & Company LLCInitiated CoverageBuy$40.00N/A
i
10/13/2016SVB LeerinkReiterated RatingOutperform$36.00N/A
i
8/10/2016Jefferies Financial GroupLower Price TargetBuy$58.00 ➝ $45.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
6/8/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
6/2/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
5/9/2016Deutsche Bank AktiengesellschaftLower Price TargetHold$42.00 ➝ $35.00N/A
i
5/5/2016JPMorgan Chase & Co.Reiterated RatingHold$37.00N/A
i
5/4/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
5/4/2016SVB LeerinkLower Price TargetOutperform$45.00 ➝ $40.00N/A
i
5/4/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
4/16/2016SVB LeerinkReiterated RatingOutperformN/A
i
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 ➝ $25.00N/A
i
3/28/2016SVB LeerinkLower Price TargetOutperform$25.00 ➝ $23.00N/A
i
3/28/2016LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
i
3/28/2016Jefferies Financial GroupUpgradeUnderperform ➝ Hold$16.00 ➝ $19.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
2/18/2016GuggenheimLower Price TargetBuy$54.00 ➝ $51.00N/A
i
1/28/2016Northland SecuritiesInitiated CoverageOutperform$40.00N/A
i
1/21/2016BarclaysInitiated CoverageEqual Weight$32.00N/A
i
1/14/2016Deutsche Bank AktiengesellschaftLower Price TargetHold$43.00 ➝ $42.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
1/3/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
12/28/2015Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
12/10/2015SVB LeerinkReiterated RatingOutperform$71.00 ➝ $45.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
11/19/2015Deutsche Bank AktiengesellschaftLower Price TargetHold$50.00 ➝ $43.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
11/12/2015Jefferies Financial GroupReiterated RatingBuy$28.95 ➝ $70.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
11/4/2015Deutsche Bank AktiengesellschaftLower Price TargetHold$58.00 ➝ $50.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
11/4/2015Jefferies Financial GroupLower Price TargetBuy$80.00 ➝ $70.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
11/2/2015Robert W. BairdBoost Price TargetOutperform$54.00 ➝ $55.00N/A
i
(Data available from 10/26/2015 forward)
AMAG Pharmaceuticals logo
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company's products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $13.69
$13.69
$13.69

50 Day Range

MA: $11.25
$8.88
$13.74

52 Week Range

Now: $13.69
$4.41
$13.80

Volume

70 shs

Average Volume

908,136 shs

Market Capitalization

$472.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03